Program
IPX203
A development code. Also written as “CREXONT ER”, “IPX203 ER CD-LD” and “IPX203 180 mg”.
Its studies are mostly in Parkinson Disease, led by Amneal Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amneal Pharmaceuticals | 51 open or running | phase 4since Dec 31, 2024 | Oct 13, 2014 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 13, 2014First study: phase 2 study in Parkinson DiseaseFirst studyNCT02271503 · 26 enrolled · United States
- Dec 6, 2016Phase 2 study in Advanced Parkinson's DiseaseNCT03007888 · 28 enrolled · United States
- Sep 12, 2018Phase 3 study in Parkinson DiseaseNCT03670953 · 630 enrolled · United States, Czechia, France and more
- Mar 12, 2019Phase 3 study in Parkinson DiseaseNCT03877510 · 419 enrolled · United States, Czechia, France and more
- Dec 31, 2024Phase 4 study in Parkinson DiseaseNCT06765668 · 220 planned · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06765668Parkinson Disease · United States | 4 | Recruiting | Nov 2025 | 220 |
| NCT03877510Parkinson Disease · United States, Czechia, France and more | 3 | Completed | Mar 21, 2022 | 419 |
| NCT03670953Parkinson Disease · United States, Czechia, France and more | 3 | Completed | Jun 15, 2021 | 630 |
| NCT03007888Advanced Parkinson's Disease · United States | 2 | Completed | Aug 1, 2017 | 28 |
| NCT02271503Parkinson Disease · United States | 2 | Completed | Aug 2016 | 26 |
How it is read
Names in the registry
- “IPX203”, 2 entries
- “CREXONT ER”, 1 entry
- “IPX203 ER CD-LD”, 1 entry
- “IPX203 180 mg”, 1 entry
- “IPX203 270 mg”, 1 entry
Codes read as this program: IPX203.
Conditions, from the studies’ own filings
- Parkinson Disease, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.